Related Experiment Videos
[Clinical experience with a new antibiotic: cefmetazole]
E De Lorenzi1, E Del Nero, M G Caviglia
1I.S.M.I., Università degli Studi di Genova.
La Clinica Terapeutica
|January 31, 1990
Summary
Cefmetazole (CMZ) is a novel antibiotic effective against a broad spectrum of Gram-positive and Gram-negative bacteria. Clinical trials show 80% effectiveness in treating various infections with minimal side effects.
Area of Science:
- Pharmacology and Microbiology
- Medicinal Chemistry
Context:
- Development of new antimicrobial agents is crucial for combating bacterial infections.
- Beta-lactamase stability is a key factor in antibiotic efficacy against resistant strains.
- Limitations of conventional cephalosporins against specific bacterial pathogens like indole-positive Proteus.
Purpose:
- To evaluate the antibacterial spectrum and clinical efficacy of cefmetazole (CMZ).
- To assess the stability of cefmetazole against beta-lactamase enzymes.
- To determine the effectiveness of CMZ in treating urinary tract, respiratory tract, and cutaneous infections.
Summary:
- Cefmetazole, a semisynthetic cephalosporin derivative with a 7-alpha-methoxy group, exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria.
- It demonstrates high stability against beta-lactamase and potent activity against indole-positive Proteus strains.
- Clinical trials involving 30 patients showed an 80% clinical and bacteriological effectiveness rate for CMZ, particularly against E. coli, Proteus, S. aureus, and K. pneumoniae, with intravenous administration of 2g daily being common.
Impact:
- Cefmetazole demonstrates significant potential as a therapeutic option for various bacterial infections.
- Its stability and efficacy against resistant strains offer a valuable addition to the antibiotic arsenal.
- The observed safety profile suggests a favorable risk-benefit ratio for clinical use.